Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

David P Schenkein

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Clinical Lung Cancer|October 28, 2005
Preclinical data with bortezomib in lung cancerDavid P Schenkein
Clinical Lung Cancer|January 11, 2005
Use of proteasome inhibition in the treatment of lung cancerDavid P Schenkein
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
Reevaluating the accelerated approval process for oncology drugsWyndham H Wilson, David P Schenkein, Cheryl L Jernigan, et al.
Blood|April 22, 2006
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDJennifer L Rocnik, Rachel Okabe, Jin-Chen Yu, et al.
Advances in Anatomic Pathology|June 29, 2004
PharmacogenomicsJeffrey S Ross, David P Schenkein, Oscar Kashala, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.
Haematologica|July 5, 2006
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib aloneSundar Jagannath, Paul G Richardson, Bart Barlogie, et al.
Cancer Metastasis Reviews|January 13, 2006
Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross, Karen E Gray, Iain J Webb, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I studyAngela M Davies, Christopher Ruel, Primo N Lara, et al.
Nature Reviews. Drug Discovery|September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsJane Fridlyand, Richard M Simon, Jessica C Walrath, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Clinical Lung Cancer|October 28, 2005
Preclinical data with bortezomib in lung cancerDavid P Schenkein
Clinical Lung Cancer|January 11, 2005
Use of proteasome inhibition in the treatment of lung cancerDavid P Schenkein
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 5, 2013
Reevaluating the accelerated approval process for oncology drugsWyndham H Wilson, David P Schenkein, Cheryl L Jernigan, et al.
Blood|April 22, 2006
Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDJennifer L Rocnik, Rachel Okabe, Jin-Chen Yu, et al.
Advances in Anatomic Pathology|June 29, 2004
PharmacogenomicsJeffrey S Ross, David P Schenkein, Oscar Kashala, et al.
Journal of the National Comprehensive Cancer Network : JNCCN|October 2, 2009
Promising activity of the proteasome inhibitor bortezomib (VELCADE) in the treatment of indolent non-Hodgkin's lymphoma and mantle cell lymphoma: ASH poster session 517-IIOwen O'Connor, John Wright, Craig H Moskowitz, et al.
Haematologica|July 5, 2006
Bortezomib in combination with dexamethasone for the treatment of patients with relapsed and/or refractory multiple myeloma with less than optimal response to bortezomib aloneSundar Jagannath, Paul G Richardson, Bart Barlogie, et al.
Cancer Metastasis Reviews|January 13, 2006
Antibody-based therapeutics: focus on prostate cancerJeffrey S Ross, Karen E Gray, Iain J Webb, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|January 2, 2008
The proteasome inhibitor bortezomib in combination with gemcitabine and carboplatin in advanced non-small cell lung cancer: a California Cancer Consortium Phase I studyAngela M Davies, Christopher Ruel, Primo N Lara, et al.
Nature Reviews. Drug Discovery|September 7, 2013
Considerations for the successful co-development of targeted cancer therapies and companion diagnosticsJane Fridlyand, Richard M Simon, Jessica C Walrath, et al.
Pageof 3